PMG treatment at doses of 50 and 100 mg/kg also produced the significant decrease in MDA level (p values < 0.05 all; compared to the HCHF+MCAO+vehicle group) together with the significant increase in SOD (p values < 0.05 and 0.001, respectively; compared to the HCHF+MCAO+vehicle group), CAT (p values < 0.01 all; compared to the HCHF+MCAO+vehicle group), and GSH-Px activities (p values < 0.05 and 0.001, respectively; compared to the HCHF+MCAO+vehicle group) in the cerebral cortex of MetS rats with MCAO. The gene discussed is SOD1; the disease is metabolic syndrome.